#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Superficial vein thrombosis Activated PI3 kinase delta syndrome T-cell type acute leukaemia Rhabdomyosarcoma recurrent Hypersomnia Crigler-Najjar syndrome Fibrosarcoma metastatic Follicle centre lymphoma follicular grade I, II – III Frostbite Acute on chronic liver failure Leukoencephalopathy Fms-like tyrosine kinase 3 positive Endocrine ophthalmopathy Pericarditis Leiomyosarcoma More trials…

    Learn about Rare Diseases

    Acute respiratory distress syndrome – Basic Information Hairy cell leukaemia recurrent – Treatment Sarcoidosis – Treatment Basal cell naevus syndrome – Treatment Glomerulonephritis rapidly progressive – Basic Information Aicardi-Goutieres syndrome Mucous membrane pemphigoid – Trials in Disease Haemophilia A with anti factor VIII – Diagnostics Pulmonary sarcoidosis – Diagnostics Phenylketonuria – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Fasudil Hydrochloride Degarelix Acetate Acetazolamide Fluasterone Ivosidenib Lolium Perenne Clindamycin Hydrochloride Pegunigalsidase Alfa Immunoglobulins, Normal Human VGA039 Abbv-668 Ramucirumab Dnth103 Soticlestat Paroxetine Hydrochloride Magnesium Citrate Tiotropium Bromide Monohydrate Dorzolamide Hydrochloride Pertechnetate (99Mtc) Sodium Obeticholic Acid More therapies…

    Learn about Your Condition

    Pulmonary tuberculosis Gallbladder cancer Substance use disorder Familial hypertriglyceridaemia Hepatic angiosarcoma Contusion Rectal adenocarcinoma Fatty acid oxidation disorder Respiratory tract infection Developmental hip dysplasia Diabetic nephropathy ROHHAD syndrome Arthralgia Anorexia nervosa Polycystic liver disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Immune System Diseases

  • A Study of Felzartamab for Kidney Transplant Patients with Late Isolated Microvascular Inflammation

    Recruiting

    2 1 1
    Investigated Diseases:
    • Renal transplant
    Investigated Drugs:
    • Felzartamab
    • Sodium Chloride
    Austria Czechia France Germany Spain

  • A study to evaluate the effects of KT-621 in adults with moderate to severe eosinophilic asthma

    Recruiting

    2 1
    Austria Belgium Germany Italy Poland Romania +2

  • Cabotegravir and Rilpivirine Ultra‑Long‑Acting vs Long‑Acting in Adults and Adolescents with HIV Who Are Virally Suppressed

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • HIV infection
    Investigated Drugs:
    • Cabotegravir
    • Rilpivirine
    Spain

  • A study testing XmAb942 compared to placebo in adults with moderate-to-severe active ulcerative colitis

    Recruiting

    2 1
    Investigated Drugs:
    • XMAB942
    Bulgaria Croatia France Germany Greece Hungary +5

  • Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Czechia France Germany Greece +9

  • Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

    Recruiting

    3 1 1
    Investigated Drugs:
    • Golimumab
    • Guselkumab
    Austria Belgium Bulgaria Czechia Denmark France +11
1 2 3 … 135
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!